ArticleDiscover oncology2026
An aging-related gene signature, featuring Cdkn2a, predicts prognosis and immunotherapy response in uterine corpus endometrial carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUterine corpus endometrial carcinoma (UCEC) is one of the three major malignant tumors of the female reproductive system, severely impacting the health and lives of young women. Cellular senescence is a hallmark of cancer and plays a role in tumor progression. This study aims to investigate the predictive and diagnostic value of aging-related genes (ARGs) in UCEC.
methodsTranscriptomic and clinical data from The Cancer Genome Atlas (TCGA) UCEC cohort were analyzed. Consensus clustering based on 432 ARGs stratified patients into subgroups. Differentially expressed genes (DEGs) were identified, and a prognostic risk model was constructed using LASSO-Cox regression. Immune infiltration, immunotherapy response, and drug sensitivity were evaluated. Functional validation of a key gene, CDKN2A (encoding P16), was performed using in vitro assays in Ishikawa cells.
resultsPatients were classified into three senescence clusters, with Cluster 3 showing the worst prognosis and an immunosuppressed phenotype. A novel 10-ARG risk signature was established and validated, effectively stratifying patients into high- and low-risk groups with distinct survival outcomes. The high-risk group exhibited an immunosuppressive microenvironment, altered immune checkpoint expression, and differential sensitivity to chemotherapy agents. CDKN2A was upregulated in UCEC tissues, and its knockdown significantly inhibited cell proliferation, migration, and promoted apoptosis in vitro.
conclusionThe novel ARGs signature is a promising biomarker for predicting the outcome of UCEC and has the potential to guide immunotherapy. As one of ARGs, Cdkn2a may be a potential diagnostic and therapeutic target for UCEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.